"What this collaboration will allow us to do is to have a member enter a pathway and answer questions to assess [the medications'] appropriateness," Gary Foster, Ph.D., WW's chief scientific officer, told "Good Morning America." "And then following that initial assessment, to connect with a clinical provider who can then determine with that individual which medications, if any, are the right path for them." Sequence currently costs $99 per month, and serves around 24,000 members across the United States
There is the need for more high-quality TEAM clinical trials to supplement existing evidence for clinical practice [37,59], of which HQT is an excellent decoction study [60]
Demand for GLP-1 therapies is likely to increase with the availability of oral forms
Metabolites 11 (2), 126 (2021)
PMID 17464988
For individuals considering allulose consumption with the goal of potentially influencing GLP-1 secretion, a cautious approach is warranted